Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
30.42
-0.06 (-0.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
November 28, 2022
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.
Via
Investor's Business Daily
This Congressman Just Purchased 2 Stocks Which Consistently Increase Dividends
November 28, 2022
Congressman Dwight Evans (D-PA) has represented Pennsylvania's Third Congressional District since 2019, and has made over 70 trades in the past three years. His top two traded investments are Intel...
Via
Benzinga
Daily Stock Analysis: Roche Holding
November 18, 2022
By my dogcatcher ideal, this is not a good time to buy Roche Holding AG shares based on their dividends for the coming year 2022-23.
Via
Talk Markets
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
Via
Benzinga
Biogen To Report Q3 Earnings: Here's What To Expect
October 21, 2022
Biogen will report third-quarter 2022 results on Oct 25, before market open.
Via
Talk Markets
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
November 16, 2022
Via
Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
Via
Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
November 15, 2022
Via
Benzinga
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
November 15, 2022
Via
Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
November 14, 2022
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.
Via
InvestorPlace
Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads
November 14, 2022
The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads.
Via
Investor's Business Daily
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Via
Benzinga
Why Is Biogen (BIIB) Stock Up Today?
November 14, 2022
Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.
Via
InvestorPlace
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
November 14, 2022
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.
Via
Investor's Business Daily
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October
November 14, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022.
Via
Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
November 14, 2022
Via
Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
November 14, 2022
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark...
Via
Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.
Via
Benzinga
6 ETFs That Are All You Need for Retirement
October 30, 2022
These yield-producing stock and bond funds are all down less than the S&P 500 this year.
Via
The Motley Fool
15 Global Psychedelics Executives To Keep An Eye On In 2022
October 28, 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...
Via
Benzinga
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 28, 2022
By Jad Malaeb, Benzinga
Via
News Direct
Topics
ETFs
Stocks
Exposures
US Equities
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 27, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.
Via
Benzinga
Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges
October 20, 2022
Via
Benzinga
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
October 18, 2022
Via
Benzinga
Market Sentiment Improves Amid Earnings Season
October 18, 2022
The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention...
Via
Talk Markets
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
October 15, 2022
Deals, financings, trials and approvals on the China biotech/pharma market.
Via
Talk Markets
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
October 13, 2022
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.
Via
Benzinga
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
October 13, 2022
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.
Via
Investor's Business Daily
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.